< Back to search results

Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

The safety and efficacy of bimekizumab in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) have not been established and it is not approved for use in AS or nr-axSpA by any regulatory authority worldwide.  The material below is provided in response to your specific search for information on UCBCOMPASS®.  It is not intended to draw any conclusion regarding the efficacy and safety of bimekizumab for any indication, dosage, or other claim.

View PDF
Download